Olaparib shows significant progression-free survival benefit in phase III SOLO2 trial
DOI:
https://doi.org/10.19156/cbn.2017.0041Abstract
No abstract available
We log anonymous usage statistics. Please read the privacy information for details.
Downloads
How to Cite
1.
Marth C. Olaparib shows significant progression-free survival benefit in phase III SOLO2 trial: . CBN [Internet]. 2017 Aug. 17 [cited 2025 May 5];5(2):3-4. Available from: https://journals.aboutscience.eu/index.php/cancerbreakingnews/article/view/177
Issue
Section
Editorial
License
Articles published in Cancer Breaking News are distributed under the CC Attribution-NonCommercial-NoDerivatives 4.0 license, which allows third parties to copy and redistribute the material providing appropriate credit and a link to the license but does not allow to use the material for commercial purposes and to use the material if it has been remixed, transformed or built upon.
Statistics
- Abstract views - 412 times
- PDF downloads - 460 times